Key Points
- Director Conor Hanley sold 5,694 Kestra shares for approximately $143,774 at $25.25 per share, reducing his stake by 47.6%. The sale was disclosed as covering tax-withholding obligations from vested equity awards.
- Kestra reported a quarterly loss of $0.67 per share, missing the $0.59 analyst consensus, while revenue reached $28.64 million. The company remains unprofitable, with analysts forecasting a full-year loss of $2.29 per share.
- Analyst sentiment is mixed, with the stock carrying an average “Hold” rating and a $28.14 consensus price target versus its recent $23.57 price. Institutional investors, including T. Rowe Price and Franklin Resources, recently increased their positions.
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) Director Kevin Reilly sold 2,932 shares of the stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $25.13, for a total value of $73,681.16. Following the completion of the transaction, the director directly owned 5,368 shares in the company, valued at approximately $134,897.84. This trade represents a 35.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Kestra Medical Technologies Stock Down 2.1%
Shares of Kestra Medical Technologies stock opened at $23.57 on Friday. Kestra Medical Technologies, Ltd. has a 12 month low of $17.34 and a 12 month high of $30.00. The business has a fifty day simple moving average of $25.42 and a 200 day simple moving average of $22.71. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16. The stock has a market cap of $1.38 billion, a PE ratio of -9.74 and a beta of 0.62.
Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The company had revenue of $28.64 million during the quarter. Research analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD lifted its stake in shares of Kestra Medical Technologies by 137.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company's stock worth $115,878,000 after acquiring an additional 2,529,851 shares during the period. California State Teachers Retirement System raised its holdings in Kestra Medical Technologies by 2,366.0% during the 2nd quarter. California State Teachers Retirement System now owns 686,422 shares of the company's stock worth $17,463,000 after purchasing an additional 658,587 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Kestra Medical Technologies by 180.8% during the fourth quarter. Franklin Resources Inc. now owns 951,008 shares of the company's stock worth $25,221,000 after buying an additional 612,343 shares during the period. Millennium Management LLC bought a new position in shares of Kestra Medical Technologies in the 1st quarter worth about $11,036,000. Finally, Brown Advisory Inc. lifted its stake in shares of Kestra Medical Technologies by 34.1% in the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company's stock valued at $44,775,000 after purchasing an additional 428,996 shares during the period.
Key Headlines Impacting Kestra Medical Technologies
Here are the key news stories impacting Kestra Medical Technologies this week:
- Positive Sentiment: Kestra appointed Daniel Finney as Vice President of Research & Development and added him to the executive leadership team. Finney has more than 20 years of Class III medical-device experience and previously led Kestra’s new product development efforts. He will oversee innovation for the Cardiac Recovery System platform, including strategic partnerships and artificial-intelligence initiatives. Kestra Names Daniel Finney Vice President of Research & Development
- Neutral Sentiment: Reported short interest was zero shares as of September 10, indicating no measurable short-selling pressure based on the filing data. However, the figure provides little incremental insight because it was also reported as zero in the prior period.
- Negative Sentiment: Four directors disclosed sales totaling about 16,424 shares worth approximately $414,000. The transactions reduced their individual holdings by roughly 9% to 48%. All four sales were explicitly made to cover tax-withholding obligations tied to vested equity awards, which makes them less bearish than discretionary open-market selling, but the cluster of transactions may still pressure sentiment. SEC insider transaction filing
- Negative Sentiment: Kestra’s latest reported quarter included an adjusted loss of $0.67 per share, worse than the $0.59 analyst consensus, alongside $28.64 million in revenue. The company remains unprofitable, increasing investor sensitivity to execution, product adoption and commercialization risks.
Wall Street Analyst Weigh In
Several equities research analysts have recently commented on KMTS shares. Weiss Ratings downgraded Kestra Medical Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a report on Monday, August 31st. JPMorgan Chase & Co. assumed coverage on Kestra Medical Technologies in a research note on Monday, August 10th. They issued an "overweight" rating and a $30.00 price target on the stock. Oppenheimer started coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a "market perform" rating on the stock. Wall Street Zen raised shares of Kestra Medical Technologies from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Finally, BTIG Research restated a "buy" rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a research report on Wednesday, September 2nd. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $28.14.
Read Our Latest Report on Kestra Medical Technologies
About Kestra Medical Technologies
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
